Literature DB >> 29748789

The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans.

Lucia Pellè1, Henrik Carlsson2, Monica Cipollini1, Alessandra Bonotti3, Rudy Foddis3, Alfonso Cristaudo3, Cristina Romei4, Rossella Elisei4, Federica Gemignani1, Margareta Törnqvist5, Stefano Landi6.   

Abstract

In a recent study, we demonstrated that the variant allele of rs2480258 within intron VIII of CYP2E1 is associated with reduced levels of mRNA, protein, and enzyme activity. CYP2E1 is the most important enzyme in the metabolism of acrylamide (AA) by operating its oxidation into glycidamide (GA). AA occurs in food, is neurotoxic and classified as a probable human carcinogen. The goal of the present study was to further assess the role of rs2480258 by measuring the rate of AA > GA biotransformation in vivo. In blood samples from a cohort of 120 volunteers, the internal doses of AA and GA were assessed by AA and GA adducts to hemoglobin (Hb) measured by mass spectrometry. The rate of biotransformation was assessed by calculating the GA-Hb/AA-Hb ratio. To maximize the statistical power, 60 TT was compared to 60 CC-homozygotes and the results showed that TT homozygotes had a statistically significant reduced rate of biotransformation. Present results reinforced the notion that T-allele of rs2480258 is a marker of low functional activity of CYP2E1. Moreover, we studied the role of polymorphisms (SNPs) within glutathione-S-transferases (GSTs) enzymes and epoxide hydrolase (EPHX), verifying previous findings that SNPs within GSTs and EPHX influence the metabolism rate.

Entities:  

Keywords:  Acrylamide; CYP2E1; Functional polymorphism; Glycidamide; Hemoglobin adducts; Xenobiotics metabolism; rs2480258

Mesh:

Substances:

Year:  2018        PMID: 29748789     DOI: 10.1007/s00204-018-2211-2

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  4 in total

1.  Cord blood acrylamide levels and birth size, and interactions with genetic variants in acrylamide-metabolising genes.

Authors:  Janneke Hogervorst; Hubert W Vesper; Narjes Madhloum; Wilfried Gyselaers; Tim Nawrot
Journal:  Environ Health       Date:  2021-04-01       Impact factor: 5.984

2.  Analysis of Acrylamide and Glycidamide in Dried Blood Spot of Smokers Using Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Yahdiana Harahap; Afaf Amma Lahilla; Anastasia Sharon Jautan; Amiral Hafidz; Sunarsih Sunarsih
Journal:  Drug Des Devel Ther       Date:  2022-02-28       Impact factor: 4.162

3.  Time Trends of Acrylamide Exposure in Europe: Combined Analysis of Published Reports and Current HBM4EU Studies.

Authors:  Michael Poteser; Federica Laguzzi; Thomas Schettgen; Nina Vogel; Till Weber; Philipp Zimmermann; Domenica Hahn; Marike Kolossa-Gehring; Sónia Namorado; An Van Nieuwenhuyse; Brice Appenzeller; Thórhallur I Halldórsson; Ása Eiríksdóttir; Line Småstuen Haug; Cathrine Thomsen; Fabio Barbone; Valentina Rosolen; Loïc Rambaud; Margaux Riou; Thomas Göen; Stefanie Nübler; Moritz Schäfer; Karin Haji Abbas Zarrabi; Liese Gilles; Laura Rodriguez Martin; Greet Schoeters; Ovnair Sepai; Eva Govarts; Hanns Moshammer
Journal:  Toxics       Date:  2022-08-17

4.  Trends of Exposure to Acrylamide as Measured by Urinary Biomarkers Levels within the HBM4EU Biomonitoring Aligned Studies (2000-2021).

Authors:  Michael Poteser; Federica Laguzzi; Thomas Schettgen; Nina Vogel; Till Weber; Aline Murawski; Phillipp Schmidt; Maria Rüther; Marike Kolossa-Gehring; Sónia Namorado; An Van Nieuwenhuyse; Brice Appenzeller; Edda Dufthaksdóttir; Kristín Olafsdóttir; Line Småstuen Haug; Cathrine Thomsen; Fabio Barbone; Valentina Rosolen; Loïc Rambaud; Margaux Riou; Thomas Göen; Stefanie Nübler; Moritz Schäfer; Karin H A Zarrabi; Liese Gilles; Laura Rodriguez Martin; Greet Schoeters; Ovnair Sepai; Eva Govarts; Hanns Moshammer
Journal:  Toxics       Date:  2022-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.